Gimenez Bruna Terada, Cezarette Gabriel Neves, Bomfim Aline de Sousa, Monteiro Wuelton Marcelo, Russo Elisa Maria de Sousa, Frantz Fabiani Gai, Sampaio Suely Vilela, Sartim Marco Aurelio
Department of Clinical Analysis, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
Center for Cell-Based Therapy and Regional Blood Center of Ribeirão Preto, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
J Venom Anim Toxins Incl Trop Dis. 2020 Nov 27;26:e20200076. doi: 10.1590/1678-9199-JVATITD-2020-0076. eCollection 2020.
Snake venom phospholipases A (svPLA) are biologically active toxins, capable of triggering and modulating a wide range of biological functions. Among the svPLAs, crotoxin (CTX) has been in the spotlight of bioprospecting research due to its role in modulating immune response and hemostasis. In the present study, novel anticoagulant mechanisms of CTX, and the modulation of inflammation-induced coagulation were investigated.
CTX anticoagulant activity was evaluated using platelet poor plasma (PPP) and whole blood (WB), and also using isolated coagulation factors and complexes. The toxin modulation of procoagulant and pro-inflammatory effects was evaluated using the expression of tissue factor (TF) and cytokines in lipopolysaccharide (LPS)-treated peripheral blood mononuclear cells (PBMC) and in WB.
The results showed that CTX impaired clot formation in both PPP and WB, and was responsible for the inhibition of both intrinsic (TF/factor VIIa) and extrinsic (factor IXa/factor VIIIa) tenase complexes, but not for factor Xa and thrombin alone. In addition, the PLA mitigated the prothrombinase complex by modulating the coagulation phospholipid role in the complex. In regards to the inflammation-coagulation cross talk, the toxin was capable of reducing the production of the pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, and was followed by decreased levels of TF and procoagulant activity from LPS-treated PBMC either isolated or in WB.
The results obtained in the present study recognize the toxin as a novel medicinal candidate to be applied in inflammatory diseases with coagulation disorders.
蛇毒磷脂酶A(svPLA)是具有生物活性的毒素,能够触发和调节多种生物学功能。在svPLA中,响尾蛇毒素(CTX)因其在调节免疫反应和止血方面的作用而成为生物勘探研究的焦点。在本研究中,研究了CTX的新型抗凝机制以及对炎症诱导凝血的调节作用。
使用贫血小板血浆(PPP)和全血(WB),以及分离的凝血因子和复合物评估CTX的抗凝活性。使用脂多糖(LPS)处理的外周血单核细胞(PBMC)和WB中组织因子(TF)和细胞因子的表达来评估毒素对促凝和促炎作用的调节。
结果表明,CTX在PPP和WB中均损害凝块形成,并且负责抑制内源性(TF/因子VIIa)和外源性(因子IXa/因子VIIIa)凝血酶原酶复合物,但不单独抑制因子Xa和凝血酶。此外,PLA通过调节复合物中凝血磷脂的作用来减轻凝血酶原酶复合物。关于炎症-凝血相互作用,该毒素能够减少促炎细胞因子IL-1β、IL-6和TNF-α的产生,随后LPS处理的PBMC(无论是分离的还是在WB中)中TF水平和促凝活性降低。
本研究获得的结果表明该毒素是一种新型药物候选物,可用于治疗伴有凝血障碍的炎症性疾病。